Recent Updates on the Role of Nanoparticles in the Treatment of Viral Diseases
- PMID: 33639068
- DOI: 10.1615/CritRevTherDrugCarrierSyst.2020034715
Recent Updates on the Role of Nanoparticles in the Treatment of Viral Diseases
Abstract
Viral infections such as AIDS, hepatitis, herpes keratitis, and herpes labialis became resistant to drugs and it is difficult to design vaccine. In current era drug-resistant viruses are now treated by nanoparticles (NPs) and this field is known as nanobiotechnology that relates nanoscience with the biological system. NPs due to their antiviral activity are used in the treatment of viral diseases. The advantages of using the NP is its specific target action and increase the efficiency of treatment with minimum side effects. Liposomes, quantum dots, polymeric NPs, solid lipid NPs, silver NPs, gold NPs, and magnetic NPs are used to treat viral infections. NP-based therapeutics have completely replaced the usage of drugs and vaccines for viral diseases treatment. Nano vaccines have been investigated for the delivery of drugs; biomaterials-based NPs are in development to be formulated into nano vaccines. But there are limitations in the manufacturing and stabilization of NPs in the body. This review focuses on the antiviral activity of several NPs, its uptake by different viruses for viral disease treatment, nano vaccines, and the limitation of the NPs as nanotherapeutics.
Similar articles
-
Nanoparticles as a novel and promising antiviral platform in veterinary medicine.Arch Virol. 2021 Oct;166(10):2673-2682. doi: 10.1007/s00705-021-05177-w. Epub 2021 Jul 23. Arch Virol. 2021. PMID: 34297222 Free PMC article. Review.
-
Antiviral drug resistance: mechanisms and clinical implications.Infect Dis Clin North Am. 2010 Jun;24(2):413-37. doi: 10.1016/j.idc.2010.01.001. Infect Dis Clin North Am. 2010. Corrected and republished in: Infect Dis Clin North Am. 2010 Sep;24(3):809-33. doi: 10.1016/j.idc.2010.07.001. PMID: 20466277 Free PMC article. Corrected and republished. Review.
-
Editorial overview: Engineering for viral resistance.Curr Opin Virol. 2015 Oct;14:v-vii. doi: 10.1016/j.coviro.2015.08.009. Epub 2015 Aug 28. Curr Opin Virol. 2015. PMID: 26320757 Free PMC article. No abstract available.
-
Current non-AIDS antiviral chemotherapy.Expert Rev Anti Infect Ther. 2007 Apr;5(2):217-30. doi: 10.1586/14787210.5.2.217. Expert Rev Anti Infect Ther. 2007. PMID: 17402837 Review.
-
Human viral diseases: what is next for antiviral drug discovery?Curr Opin Virol. 2012 Oct;2(5):572-9. doi: 10.1016/j.coviro.2012.07.004. Epub 2012 Jul 28. Curr Opin Virol. 2012. PMID: 22846888 Review.
Cited by
-
Hyaluronic Acid-Silver Nanocomposites and Their Biomedical Applications: A Review.Materials (Basel). 2021 Dec 29;15(1):234. doi: 10.3390/ma15010234. Materials (Basel). 2021. PMID: 35009380 Free PMC article. Review.
-
Ethosomal Gel for Topical Administration of Dimethyl Fumarate in the Treatment of HSV-1 Infections.Int J Mol Sci. 2023 Feb 18;24(4):4133. doi: 10.3390/ijms24044133. Int J Mol Sci. 2023. PMID: 36835541 Free PMC article.
-
The Intellectual Landscape of Nanovaccines: A Bibliometric Perspective on Scientific Progress and Future Directions.Cureus. 2024 May 12;16(5):e60131. doi: 10.7759/cureus.60131. eCollection 2024 May. Cureus. 2024. PMID: 38868255 Free PMC article. Review.
-
Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.Daru. 2024 Dec;32(2):801-823. doi: 10.1007/s40199-024-00524-z. Epub 2024 Jul 19. Daru. 2024. PMID: 39026019 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous